Home > Boards > US Listed > Cannabis > Zynerba Pharmaceuticals (ZYNE)

OK...Ready to go into ZANERBA MODE.From looks of things

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
dhbuzz Member Profile
 
Followed By 10
Posts 2,831
Boards Moderated 0
Alias Born 03/01/19
160x600 placeholder
Zynerba Pharma pops 4% after securing new European patent for Zygel CBD gel Seeking Alpha - 11/22/2021 8:03:44 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/22/2021 7:23:52 AM
Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™ GlobeNewswire Inc. - 11/22/2021 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/15/2021 7:35:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/15/2021 7:24:52 AM
Zynerba Pharmaceuticals EPS misses by $0.01 Seeking Alpha - 11/15/2021 7:24:29 AM
Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights GlobeNewswire Inc. - 11/15/2021 7:00:00 AM
Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October GlobeNewswire Inc. - 10/21/2021 7:00:00 AM
Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit GlobeNewswire Inc. - 10/19/2021 4:15:00 PM
Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition GlobeNewswire Inc. - 10/8/2021 7:30:00 AM
Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/20/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2021 7:13:01 AM
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome GlobeNewswire Inc. - 9/13/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/9/2021 7:11:22 AM
Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 GlobeNewswire Inc. - 9/9/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/7/2021 7:11:28 AM
Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open GlobeNewswire Inc. - 9/7/2021 7:00:00 AM
Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire Inc. - 9/2/2021 7:30:00 AM
Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 GlobeNewswire Inc. - 9/2/2021 7:00:00 AM
Zymergen Investor Alert - Klafter Lesser LLP, a Highly Accomplished Class Action Law Firm, Announces That a Class Action Has Been Filed Business Wire - 8/11/2021 5:30:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/9/2021 7:32:15 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2021 7:08:05 AM
Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights GlobeNewswire Inc. - 8/9/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/5/2021 5:29:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/5/2021 5:27:43 PM
dhbuzz   Sunday, 05/31/20 08:18:30 PM
Re: None
Post # of 2660 
OK...Ready to go into ZANERBA MODE.From looks of things

this could become one of the most interesting weeks in some time with the recent options market behavior.Close eye on tomarrow mornings pre market.

Look forward to Jefferies presentation Tue.Also DEES guidence from FDA,and last ,but not least FX results in June hopefully.

GLTA

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences